David S Goldfarb

Summary

Country: USA

Publications

  1. doi request reprint Evidence for inheritance of medullary sponge kidney
    David S Goldfarb
    Nephrology Division, New York University Langone Medical Center, Nephrology Section, Veterans Affairs New York Harbor Healthcare System, New York, New York 10010, USA
    Kidney Int 83:193-6. 2013
  2. doi request reprint Metabolic evaluation of first-time and recurrent stone formers
    David S Goldfarb
    New York University School of Medicine, New York, NY 10016, USA
    Urol Clin North Am 40:13-20. 2013
  3. doi request reprint A woman with recurrent calcium phosphate kidney stones
    David S Goldfarb
    Nephrology Section, New York Harbor Department of Veterans Affairs Healthcare System, New York, NY 10010, USA
    Clin J Am Soc Nephrol 7:1172-8. 2012
  4. pmc Potential pharmacologic treatments for cystinuria and for calcium stones associated with hyperuricosuria
    David S Goldfarb
    Nephrology Section 111G, NY DVAMC, 423 E 23 Street, New York, NY 10010, USA
    Clin J Am Soc Nephrol 6:2093-7. 2011
  5. doi request reprint Prevalence of contraindications and prescription of pharmacologic therapies for gout
    Robert T Keenan
    Section of Rheumatology of the New York Harbor Health Care System, New York Campus of the US Department of Veterans Affairs, New York, USA
    Am J Med 124:155-63. 2011
  6. doi request reprint Update on cystinuria
    Nicola Sumorok
    Nephrology Section, New York Harbor VA Healthcare System, and Nephrology Division, New York University School of Medicine, New York, New York, USA
    Curr Opin Nephrol Hypertens 22:427-31. 2013
  7. doi request reprint Effect of vitamin D repletion on urinary calcium excretion among kidney stone formers
    David E Leaf
    Department of Medicine, Columbia University, New York, New York, USA
    Clin J Am Soc Nephrol 7:829-34. 2012
  8. doi request reprint Febuxostat in gout: serum urate response in uric acid overproducers and underexcretors
    David S Goldfarb
    New York Veterans Affairs Medical Center, New York, NY, USA
    J Rheumatol 38:1385-9. 2011
  9. ncbi request reprint A randomized, controlled trial of lactic acid bacteria for idiopathic hyperoxaluria
    David S Goldfarb
    Nephrology Section, New York Harbor VA Medical Center and New York University School of Medicine, New York, NY 10010, USA
    Clin J Am Soc Nephrol 2:745-9. 2007
  10. ncbi request reprint Randomized controlled trial of clopidogrel plus aspirin to prevent hemodialysis access graft thrombosis
    James S Kaufman
    Department of Veterans Affairs Boston Healthcare System and Department of Medicine, Boston University School of Medicine, Boston, Massachusetts 02130, USA
    J Am Soc Nephrol 14:2313-21. 2003

Collaborators

Detail Information

Publications38

  1. doi request reprint Evidence for inheritance of medullary sponge kidney
    David S Goldfarb
    Nephrology Division, New York University Langone Medical Center, Nephrology Section, Veterans Affairs New York Harbor Healthcare System, New York, New York 10010, USA
    Kidney Int 83:193-6. 2013
    ..Although a small proportion of MSK cases are associated with variants of glial cell-derived neurotrophic factor (GDNF), the genetic basis for most instances of MSK is not known...
  2. doi request reprint Metabolic evaluation of first-time and recurrent stone formers
    David S Goldfarb
    New York University School of Medicine, New York, NY 10016, USA
    Urol Clin North Am 40:13-20. 2013
    ..Although twin studies demonstrate that heritability accounts for at least 50% of the kidney stone phenotype, the responsible genes are not clearly identified, and so genetic testing is rarely indicated...
  3. doi request reprint A woman with recurrent calcium phosphate kidney stones
    David S Goldfarb
    Nephrology Section, New York Harbor Department of Veterans Affairs Healthcare System, New York, NY 10010, USA
    Clin J Am Soc Nephrol 7:1172-8. 2012
    ..Thiazides lower urine calcium excretion and may help ensure the safety of citrate supplementation...
  4. pmc Potential pharmacologic treatments for cystinuria and for calcium stones associated with hyperuricosuria
    David S Goldfarb
    Nephrology Section 111G, NY DVAMC, 423 E 23 Street, New York, NY 10010, USA
    Clin J Am Soc Nephrol 6:2093-7. 2011
    ..In vitro, l-cystine dimethyl ester had a significant inhibitory effect on crystal growth. The drug's safety and effectiveness will be tested in an Slc3a1 knockout mouse that serves as an animal model of cystinuria...
  5. doi request reprint Prevalence of contraindications and prescription of pharmacologic therapies for gout
    Robert T Keenan
    Section of Rheumatology of the New York Harbor Health Care System, New York Campus of the US Department of Veterans Affairs, New York, USA
    Am J Med 124:155-63. 2011
    ..Patients with gout have comorbidities, but the impact of these comorbidities on treatment has not been studied...
  6. doi request reprint Update on cystinuria
    Nicola Sumorok
    Nephrology Section, New York Harbor VA Healthcare System, and Nephrology Division, New York University School of Medicine, New York, New York, USA
    Curr Opin Nephrol Hypertens 22:427-31. 2013
    ..Treatment is focused on the prevention of stone formation. There have been few advances in the available therapeutic options for the disorder in the last 15-20 years...
  7. doi request reprint Effect of vitamin D repletion on urinary calcium excretion among kidney stone formers
    David E Leaf
    Department of Medicine, Columbia University, New York, New York, USA
    Clin J Am Soc Nephrol 7:829-34. 2012
    ..This study examined the effect of vitamin D repletion on urinary calcium excretion among stone formers...
  8. doi request reprint Febuxostat in gout: serum urate response in uric acid overproducers and underexcretors
    David S Goldfarb
    New York Veterans Affairs Medical Center, New York, NY, USA
    J Rheumatol 38:1385-9. 2011
    ..The objective of this post-hoc analysis was to determine the effectiveness of the xanthine oxidase inhibitor febuxostat in reducing serum urate (sUA) levels in gouty patients who were either overproducers or underexcretors...
  9. ncbi request reprint A randomized, controlled trial of lactic acid bacteria for idiopathic hyperoxaluria
    David S Goldfarb
    Nephrology Section, New York Harbor VA Medical Center and New York University School of Medicine, New York, NY 10010, USA
    Clin J Am Soc Nephrol 2:745-9. 2007
    ..Some lactic acid bacteria can degrade oxalate in vitro. This study sought to reduce urinary oxalate excretion in calcium stone formers with idiopathic hyperoxaluria...
  10. ncbi request reprint Randomized controlled trial of clopidogrel plus aspirin to prevent hemodialysis access graft thrombosis
    James S Kaufman
    Department of Veterans Affairs Boston Healthcare System and Department of Medicine, Boston University School of Medicine, Boston, Massachusetts 02130, USA
    J Am Soc Nephrol 14:2313-21. 2003
    ..22 to 1.26; P = 0.14). In the hemodialysis population, therapy with aspirin and clopidogrel was associated with a significantly increased risk of bleeding and probably would not result in a reduced frequency of graft thrombosis...
  11. ncbi request reprint Predictive value of a positive fecal occult blood test increases as the severity of CKD worsens
    Edmund J Bini
    Division of Gastroenterology, Veterans Affairs New York Harbor Healthcare System, New York, NY 10010, USA
    Am J Kidney Dis 48:580-6. 2006
    ....
  12. ncbi request reprint A twin study of genetic and dietary influences on nephrolithiasis: a report from the Vietnam Era Twin (VET) Registry
    David S Goldfarb
    Nephrology Section, New York Harbor VAMC, New York, NY, USA
    Kidney Int 67:1053-61. 2005
    ..Nephrolithiasis is a complex phenotype that is influenced by both genetic and environmental factors. We conducted a large twin study to examine genetic and nongenetic factors associated with stones...
  13. ncbi request reprint Microorganisms and calcium oxalate stone disease
    David S Goldfarb
    New York Harbor VA Medical Center and NYU School of Medicine, New York, NY 10010, USA
    Nephron Physiol 98:p48-54. 2004
    ..formigenes which codes for that organism's oxalate uptake mechanism. The author is currently completing a small randomized controlled clinical trial with this preparation in calcium stone-forming patients with idiopathic hyperoxaluria...
  14. ncbi request reprint How life imitates baseball
    David S Goldfarb
    Nephrology Section, New York VA Medical Center, New York University School of Medicine, USA
    Pharos Alpha Omega Alpha Honor Med Soc 67:34-5. 2004
  15. doi request reprint Optimal medical therapy with or without percutaneous coronary intervention for patients with stable coronary artery disease and chronic kidney disease
    Steven P Sedlis
    New York University School of Medicine, New York, NY, USA
    Am J Cardiol 104:1647-53. 2009
    ..Although PCI did not reduce the risk of death or myocardial infarction when added to OMT for patients with CKD, it also was not associated with worse outcomes in this high-risk group...
  16. pmc A pilot study of the effect of sodium thiosulfate on urinary lithogenicity and associated metabolic acid load in non-stone formers and stone formers with hypercalciuria
    Onyeka W Okonkwo
    Department of Medicine, New York Harbor VA Healthcare System and NYU School of Medicine, New York, New York, United States of America
    PLoS ONE 8:e60380. 2013
    ..Results were compared by non-parametric Wilcoxon signed rank test. The primary outcome was the resulting change in urine chemistry...
  17. doi request reprint Crystal growth inhibitors for the prevention of L-cystine kidney stones through molecular design
    Jeffrey D Rimer
    Department of Chemistry and the Molecular Design Institute, New York University NYU, 100 Washington Square East, New York, NY 10003 6688, USA
    Science 330:337-41. 2010
    ..The AFM observations are mirrored by reduced crystal yield and crystal size in the presence of L-CDME and L-CME, collectively suggesting a new pathway to the prevention of L-cystine stones by rational design of crystal growth inhibitors...
  18. doi request reprint Update on the pathophysiology and management of uric acid renal stones
    Jon Emile S Kenny
    Department of Medicine, NYU Langone Medical Center, New York, NY, USA
    Curr Rheumatol Rep 12:125-9. 2010
    ..We review recent evidence from both the molecular and clinical realms to underline the importance of [H+] in the development and treatment of uric acid nephrolithiasis...
  19. pmc Randomized controlled trial of febuxostat versus allopurinol or placebo in individuals with higher urinary uric acid excretion and calcium stones
    David S Goldfarb
    Nephrology Section, New York Harbor VA Medical Center, and Division of Nephrology, New York University Langone Medical Center, New York, New York, Global Medical Affairs, Takeda Pharmaceuticals International, Deerfield, Illinois, Clinical Science, and Statistics, Takeda Global Research and Development Center, Inc, Deerfield, Illinois, Experimental Medicine, Takeda California, San Diego, California
    Clin J Am Soc Nephrol 8:1960-7. 2013
    ..This work studied whether febuxostat, compared with allopurinol and placebo, would reduce 24-hour urinary uric acid excretion and prevent stone growth or new stone formation...
  20. doi request reprint Surgical decompression is associated with decreased mortality in patients with sepsis and ureteral calculi
    Michael S Borofsky
    Department of Urology, Nephrology Division and Section on Value and Effectiveness, New York University Langone Medical Center, New York University, New York, New York 10016, USA
    J Urol 189:946-51. 2013
    ..We determined whether a mortality benefit is associated with this intervention...
  21. doi request reprint Uric acid stones and hyperuricosuria
    Tapan H Mehta
    Department of Medicine, New York University Langone Medical Center, New York, NY, USA
    Adv Chronic Kidney Dis 19:413-8. 2012
    ..The cornerstone of therapy is raising urinary pH; xanthine dehydrogenase inhibitors should be used only when urinary alkalinization cannot be achieved...
  22. pmc Progressive renal papillary calcification and ureteral stone formation in mice deficient for Tamm-Horsfall protein
    Yan Liu
    Dept of Urology, New York Univ School of Medicine, NY 10010, USA
    Am J Physiol Renal Physiol 299:F469-78. 2010
    ....
  23. doi request reprint Effect of two sports drinks on urinary lithogenicity
    Jeffrey W Goodman
    NYU School of Medicine, New York, NY 10010, USA
    Urol Res 37:41-6. 2009
    ..Most sports drinks with significant carbohydrate content however may contain too many calories, and fructose, to be preferred beverages for stone prevention...
  24. doi request reprint Effect of diet orange soda on urinary lithogenicity
    Nicola T Sumorok
    Department of Medicine and Nephrology Division, NYU Langone Medical Center, New York, NY, USA
    Urol Res 40:237-41. 2012
    ..The effect of Diet Sunkist Orange soda on urinary chemistry in patients with hypocitraturia and nephrolithiasis is not likely to have a clinically significant effect to prevent calcium or uric acid stones...
  25. doi request reprint Melamine-related kidney stones and renal toxicity
    Rishikesh P Dalal
    Department of Medicine, NYU Langone Medical Center, 550 First Avenue, New York, NY 10016, USA
    Nat Rev Nephrol 7:267-74. 2011
    ..Finally, the public health measures taken in the wake of the melamine contamination events are discussed...
  26. doi request reprint Ambient temperature as a contributor to kidney stone formation: implications of global warming
    Robert J Fakheri
    New York University School of Medicine, New York, USA
    Kidney Int 79:1178-85. 2011
    ..At this time the limited data available cannot substantiate this proposed mechanism but further studies to investigate this effect are warranted...
  27. pmc A pilot clinical study to evaluate changes in urine osmolality and urine cAMP in response to acute and chronic water loading in autosomal dominant polycystic kidney disease
    Irina Barash
    Department of Medicine, Division of Nephrology, 550 First Avenue, New York, NY 10016, USA
    Clin J Am Soc Nephrol 5:693-7. 2010
    ..Water loading, by suppressing arginine vasopressin (AVP)-stimulated cAMP production, is a proposed therapy for ADPKD...
  28. ncbi request reprint Gout and its comorbidities
    Michael H Pillinger
    New York University School of Medicine, NYU Hospital for Joint Diseases, New York, NY 10003, USA
    Bull NYU Hosp Jt Dis 68:199-203. 2010
    ..In addition, we briefly consider several neurological conditions in which the presence of gout or a high serum urate level may be associated with less disease, rather than more...
  29. doi request reprint Prospects for dietary therapy of recurrent nephrolithiasis
    David S Goldfarb
    Nephrology Division, NYU School of Medicine, New York, NY, USA
    Adv Chronic Kidney Dis 16:21-9. 2009
    ..Because the efficacy of thiazides in the prevention of stones in patients with hypercalciuria is clear, I propose dietary comparison of higher calcium intake to thiazides for the prevention of calcium-based kidney stones...
  30. pmc Asymptomatic nephrolithiasis detected by ultrasound
    Amar D Bansal
    Department of Medicine, New York University School of Medicine, New York, New York, USA
    Clin J Am Soc Nephrol 4:680-4. 2009
    ..However, these studies have not analyzed the effect that increases in utilization of imaging modalities have had on detection of asymptomatic stones...
  31. ncbi request reprint Chitosan does not reduce post-prandial urinary oxalate excretion
    Joshua Wolf
    Nephrology Section, University of California at San Francisco Medical Center, San Francisco, CA, and Nephrology Section, New York Harbor VAMC, Department of Urology, St Vincents Hospital, New York, NY 10010, USA
    Urol Res 34:227-30. 2006
    ..3+/-16.9 mg/g creatinine (P=0.57, NS). We conclude that chitosan does not reduce acute intestinal oxalate absorption and therefore does not affect post-prandial urinary oxalate excretion...
  32. ncbi request reprint The role of continuous renal replacement therapy in the treatment of poisoning
    Jeffrey W Goodman
    Nephrology Section, New York Harbor VA Medical Center, New York, New York 10010, USA
    Semin Dial 19:402-7. 2006
    ..We believe that the intelligent application of extracorporeal modalities requires a thorough knowledge of drug pharmacokinetics, of the techniques utilized, and a skeptical analysis of the available literature...
  33. doi request reprint Treatment of pregabalin toxicity by hemodialysis in a patient with kidney failure
    Lawrence Yoo
    Division of Nephrology, New York University Medical Center, New York, NY 10010, USA
    Am J Kidney Dis 54:1127-30. 2009
    ..23 Da), relatively low volume of distribution (0.5 L/kg), and not bound to plasma proteins. We achieved hemodialysis clearance of 88.8 mL/min, which was associated with resolution of symptoms immediately after hemodialysis...
  34. ncbi request reprint The sorcerer's stone
    David S Goldfarb
    Kidney Stone Prevention Programs, New York VA Medical Center, New York, NY, USA
    Pharos Alpha Omega Alpha Honor Med Soc 69:36-7. 2006
  35. doi request reprint Use of hemodialysis and hemoperfusion in poisoned patients
    William J Holubek
    Department of Emergency Medicine, New York Methodist Hospital, New York, New York, USA
    Kidney Int 74:1327-34. 2008
    ..Our study shows that the profile of toxins and the type of extracorporeal technique used to remove the toxins have changed over the years...
  36. ncbi request reprint Nephrolithiasis complicating treatment of diabetes insipidus
    Saurabh Mehandru
    Kidney Stone Prevention Program, New York VA Medical Center, New York, USA
    Urol Res 33:244-6. 2005
    ..The challenge of the management of stones in the setting of DI requires balancing the conflicting goals of both decreasing and increasing urine volume...
  37. ncbi request reprint Patients at the center: in our practice, and in our use of language
    David S Goldfarb
    New York Harbor VA Medical Center, NYU School of Medicine, New York, New York, USA
    ACP J Club 140:A14; author reply A14-5. 2004
  38. doi request reprint Interpretation and review of health-related quality of life data in CKD patients receiving treatment for anemia
    David E Leaf
    Department of Medicine, New York University School of Medicine, New York, New York, USA
    Kidney Int 75:15-24. 2009
    ..Beyond this range, additional normalization of hemoglobin (to 12-14 g/dl) results in continued (albeit blunted) improvements in HRQOL...